Pharma Giant Stada Aims for IPO Amid Debt Concerns

Stada, a pharmaceutical company based in Hesse, Germany, is planning a public offering this fall, despite facing significant debt challenges. CEO Peter Goldschmidt expressed confidence in the company's improved position since an earlier attempt to list in the spring was thwarted by market volatility following "Liberation Day," a term associated with significant policy shifts in the U.S. under the Trump administration. Goldschmidt highlighted Stada's expanded drug pipeline and strong European presence as positive indicators for the upcoming IPO.

The initial attempt to go public was postponed due to an unstable market environment. However, the situation has since stabilized, allowing Stada to plan a second attempt. The company aims for a valuation of approximately 10 billion euros, which could facilitate its entry into Germany's MDAX index, a benchmark for mid-cap companies. Stada's recent performance includes a record 50 new licensing agreements in the first half of the year, positioning it alongside other major firms like Verisure and Shawbrook Group that are also preparing for public listings. This activity could inject new energy into Europe's capital markets, which have experienced a slow start. Despite these optimistic developments, Stada's financial health poses potential risks for investors.

The company, owned by private equity firms Bain Capital and Cinven, carries a debt of about 5.7 billion euros. The IPO is expected to help reduce this by around 3 billion euros, leaving net debt at roughly three times the adjusted operating profit. Investors may weigh these liabilities against successful benchmarks such as Dermapharm and Sandoz, which are already publicly traded. Financially, Stada has been performing well, with a six percent increase in adjusted revenues, totaling 2.1 billion euros in the first half of the year. The company's EBITDA also rose by five percent to 481 million euros. A major contributor to this growth is Uzpruvo, a biosimilar version of the psoriasis treatment Stelara, originally developed by Johnson & Johnson, which is projected to generate over 6 billion dollars in revenue this year. As Stada prepares for its IPO, investors will need to consider both the potential for growth and the challenges posed by its existing debt. The success of this venture could set a precedent for other pharmaceutical companies considering similar strategies in the volatile market landscape.